158 related articles for article (PubMed ID: 23964174)
1. HPTLC-densitometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in dry powder inhalers.
Kasaye L; Hymete A; Mohamed AM
Saudi Pharm J; 2010 Jul; 18(3):153-9. PubMed ID: 23964174
[TBL] [Abstract][Full Text] [Related]
2. Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form.
Thomas AB; Patil SD; Nanda RK; Kothapalli LP; Bhosle SS; Deshpande AD
Saudi Pharm J; 2011 Oct; 19(4):221-31. PubMed ID: 23960763
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantitative determinations of fluticasone propionate and salmeterol xinafote in diskus inhalers.
Duran A; Dogan HN; Ulgen M
Drug Metab Lett; 2014; 8(1):31-5. PubMed ID: 25313021
[TBL] [Abstract][Full Text] [Related]
4. [Systematic review and Meta-analysis on efficacy and safety of Liujunzi Decoction combined with Western medicine for stable chronic obstructive pulmonary disease].
Yi-Ling F; Qing M; Xing L; Chang-Zheng F; Mao-Rong F; Qing C; Ning W; Qiu-Xiao MA; Ya-Ni H
Zhongguo Zhong Yao Za Zhi; 2020 Nov; 45(22):5331-5343. PubMed ID: 33350192
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
[TBL] [Abstract][Full Text] [Related]
6. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Markham A; Adkins JC
Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a high-performance thin layer chromatography method for the simultaneous determination of amoxicillin and clavulanic acid combinations in tablet dosage forms.
Asres E; Layloff T; Ashenef A
Heliyon; 2023 Dec; 9(12):e22891. PubMed ID: 38144316
[TBL] [Abstract][Full Text] [Related]
8. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
[TBL] [Abstract][Full Text] [Related]
11. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
12. Development of a sensitive method for simultaneous determination of fluticasone propionate and salmeterol in plasma samples by liquid chromatography-tandem mass spectrometry.
Silvestro L; Savu SR; Savu SN; Tudoroniu A; Tarcomnicu I
Biomed Chromatogr; 2012 May; 26(5):627-35. PubMed ID: 22577660
[TBL] [Abstract][Full Text] [Related]
13. The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments.
Michael Y; Chowdhry BZ; Ashurst IC; Snowden MJ; Davies-Cutting C; Gray S
Int J Pharm; 2000 May; 200(2):279-88. PubMed ID: 10867258
[TBL] [Abstract][Full Text] [Related]
14. HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms.
Eric-Jovanovic S; Agbaba D; Zivanov-Stakic D; Vladimirov S
J Pharm Biomed Anal; 1998 Dec; 18(4-5):893-8. PubMed ID: 9919994
[TBL] [Abstract][Full Text] [Related]
15. Determination of salmeterol, α-hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS.
Sakellariou P; Petrou M; Lyris E; Tsivou M; Fragkaki A; Kiousi P; Angelis YS; Pistos C
Biomed Chromatogr; 2021 Aug; 35(8):e5114. PubMed ID: 33720401
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[TBL] [Abstract][Full Text] [Related]
17. Application of a Stability-Indicating HPTLC Method for Simultaneous Quantitative Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Pharmaceutical Dosage Forms.
Ilango K; Shiji Kumar PS
J Anal Methods Chem; 2013; 2013():363741. PubMed ID: 24319604
[TBL] [Abstract][Full Text] [Related]
18. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
Kirby S; Falcoz C; Daniel MJ; Milleri S; Squassante L; Ziviani L; Ventresca GP
Eur J Clin Pharmacol; 2001; 56(11):781-91. PubMed ID: 11294367
[TBL] [Abstract][Full Text] [Related]
19. Salmeterol/fluticasone propionate combination.
Spencer CM; Jarvis B
Drugs; 1999 Jun; 57(6):933-40; discussion 941-3. PubMed ID: 10400406
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
Aubier M; Pieters WR; Schlösser NJ; Steinmetz KO
Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
